The Precision Peptide Company Inc.

CSE: BPC | OTCQB: PNGAF

Research Corporate Presentation

Latest News: The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited

The Last Peptide Wave Built a $1 Trillion Company. RFK Jr. Just Opened the Door to Twelve More

View Source References

Disseminated on behalf of The Precision Peptide Company

The Precision Peptide Company logo: a black circle with a white curved stripe beside the company name

SYMBOL | CSE: BPC | OTCQB: PNGAF

The Precision Peptide Company (CSE: BPC) is a Vancouver-based natural supplement company that operates  in Surrey, British Columbia. As the parent company of Amino Innovations, the Precision Peptide team delivers science-backed, non-invasive, highly effective solutions that naturally align with biology.

No gimmicks. No shortcuts. Just real results.BPC

Marketing banner for First to Market Consumer Portfolio showing four rounded panels with biotech imagery and product boxes labeled Recovery, Cognitive, Longevity, and Dermal.

Market Position

The FDA just cleared twelve more peptides for review. The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) is the publicly traded small-cap already selling them. Delivered through a patch. Not a syringe.

The Category That Dethroned Cancer Immunotherapy...All Four are Peptides.

By mid-2024, the entire top-selling drug list had transformed. Immunology and oncology biologics were displaced, and peptides moved into the top ranks.

Semaglutide, the GLP-1 behind Wegovy and Ozempic, turned Novo Nordisk from a mid-cap into the most valuable company in Europe by August 2023, briefly surpassing LVMH⁶.

Tirzepatide, the GLP-1 in Zepbound and Mounjaro, pushed Eli Lilly past US$1 trillion in market capitalization on November 21, 2025 — the first healthcare company in history to cross that threshold⁷.

In the third quarter of 2025 alone, tirzepatide generated US$10.11 billion, eclipsing Merck’s Keytruda as the best-selling drug franchise on Earth⁸.

Accelerating Into the Mainstream

Consumer demand for peptide therapies has moved into mainstream channels. Search volume for BPC-157 hit an all-time high in June 2024, and combined TikTok and YouTube views for #BPC157 have surpassed 50 million, according to a 2025 systematic review in HSS Journal¹¹.

Needle-Free Delivery Unlocks Widespread Adoption

Peptides became the biggest drug class in pharma – even with self-injection as the primary delivery method. But for many consumers, that requirement remains a barrier.

The published data on how adults feel about needles is unambiguous:

  • 2% of adults experience needle phobia, according to a 2022 international study of 2,098 adults published in PLOS ONE¹⁶.
  • Between 11.5 and 66 million U.S. adults may suffer from the clinical condition, per the Journal of Primary Care & Community Health¹⁷.
  • Patients prefer a daily oral medication over a weekly injectable by approximately 3 to 1 when efficacy is equivalent, per the peer-reviewed REVISE study¹⁸.

That is a key barrier to growth in the peptide market – one The Precision Peptide Company (CSE: BPC | OTCQB: PNGAF) has built its product portfolio to address.

Through its subsidiary, Amino Innovations, Precision Peptide develops the following formulas in patent-pending oral and topical formats:

    • BPC-157 (Recovery)
    • GHK-Cu (Dermal)
    • KPV (Anti-Inflammatory)

And in October 2025, the Company announced its next-generation peptide patch platform — an innovation that expects to redefine peptide delivery¹⁹.

The Amino Innovations Patch uses bio-dissolving lattice technology to deliver peptides through the skin’s surface layers.

No pain. No mixing. No needles.

Its proprietary design achieves one-to-one equivalence to traditional injectable dosing. Thereby eliminating the reconstitution, sterile handling, and dosing measurement that have made peptides a clinical specialty rather than an everyday wellness product¹⁹.

The patches are compact, TSA-friendly, and shelf-stable for up to six months — no refrigeration, no preparation, no pharmacy visit needed.

Every patch is developed in the United States, manufactured in a cGMP-certified facility, and subject to rigorous third-party testing for pharmaceutical-grade purity, stability, and consistency¹⁹.

Line of supplement bottles labeled Ageless, Blue, BPC, Chill, and KPV, plus Hair serum and Skin cream, with The Precision Peptide Company logo in the background.

Corporate Presentation

View/Download Presentation

Peptide's Explain

A Bright Future Ahead...

“My hope is that they will get moved to a place where people have access from ethical suppliers.”

— Secretary Kennedy, JRE #2461, February 27, 2026²

Source: Peptide Therapeutics Market Forecast

Research Has Been Building for Decades

Peptides are among the most studied molecules in modern medicine. These short amino acid chains act as biological messengers — regulating inflammation, tissue repair, metabolism, immune function, and cellular signalling.

According to the THPdb database published in PLOS ONE, the FDA has approved hundreds of peptide and peptide-protein therapeutics to date²⁵.

Insulin. Semaglutide. Tirzepatide. Liraglutide. Teriparatide. Octreotide. Leuprolide. Desmopressin. Oxytocin. Bremelanotide. Tesamorelin.

All peptides. All approved. All already in the pharmaceutical mainstream.

The specific compounds now under PCAC review carry decades of independent research behind them:

  • GHK-Cu was first characterised in a 1980 Nature paper by Loren Pickart as a copper-binding plasma tripeptide. Subsequent research has linked it to the modulation of more than 4,000 human genes, with research exploring its role in wound healing and dermatological health.²⁶
  • BPC-157 has been studied continuously since 1991 by the research group of Dr. Predrag Sikiric at the University of Zagreb, with dozens of peer-reviewed publications on tissue healing and angiogenesis²⁷.
  • MOTS-c was discovered by USC researchers and published in Cell Metabolism in 2015 as the first functional mitochondrial-encoded peptide beyond humanin²⁸. New research is focusing on potential applications in metabolic disorders, including type 2 diabetes and metabolic syndrome
  • Epitalon research, pioneered by Dr. Vladimir Khavinson in St. Petersburg, was independently replicated in 2025 by researchers at Brunel University London²⁹. It’s now being studied for its potential effects on age-related cellular decline.

This is not a new frontier. It is the most-published, longest-studied “new” drug class in medicine.

Management & Board of Directors

Pratap Sandhu
Chief Executive Officer

A visionary entrepreneur with deep roots in food manufacturing, Pratap transformed his family’s business from a small operation to a global success. With his BCIT background in marketing and professional sales, he leads Pangea’s strategic direction and growth initiatives.

Nashir Virani
Director

Food industry pioneer and former CEO of Golden Boy Foods, which he grew from a coffee business to a diversified food manufacturer before its US$500 million acquisition by Kraft in 2015. Currently CEO of First Choice Foods, Nashir brings invaluable industry expertise.

Ajit Bhatti
Director

A technology and investment veteran with 19 years of leadership experience, Ajit specializes in large-scale project implementation and venture capital investments. His expertise spans healthcare, technology, and mineral exploration.

Recent News

Must Read OTC Markets/SEC policy on stock promotion and investor protection

COMPENSATION DISCLOSURE

EMC has been paid $150,000 by Pangea Wellness Inc./The Precision Peptide Company | Please read our full disclaimer

Disclaimer and Forward Looking Statements

This website contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). All statements on this website, other than statements of historical fact, are forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to:

  • the Company’s corporate objectives, business strategy, and long-term aspirations, including its mission to expand access to next-generation peptide technologies;
  • the Company’s research and development activities relating to its peptide-based formulations and drug delivery platforms, including its advanced transdermal and oral delivery systems;
  • the anticipated applications and benefits of the Company’s peptide products and technologies;
  • the Company’s plans to expand and scale its distribution network across North American clinical, consumer, and performance-driven markets;
  • the anticipated market opportunity in the North American peptide-based wellness industry, including statements regarding the growth of the peptide segment;
  • the Company’s plans to enter into licensing, partnership, collaboration, manufacturing, or other commercial agreements in connection with its products and delivery platforms;
  • the Company’s plans with respect to future financing and the anticipated use of proceeds therefrom;
  • expectations regarding revenues, expenses, and future financial performance; and
  • any other information as to the future plans and outlook for the Company.

Forward-looking statements are frequently identified by words and phrases such as “aims,” “anticipates,” “believes,” “continues to,” “designed for,” “estimates,” “expects,” “focused on,” “forecasts,” “future,” “guidance,” “in development,” “intends,” “may,” “might,” “objective,” “outlook,” “plans,” “potential,” “projected,” “pursue,” “reimagined,” “scheduled,” “seeks,” “should,” “strategy,” “targets,” “will,” “will be achieved,” “will occur,” or variations of such words and expressions, or statements that certain actions, events, or results “could,” “would,” or “might” occur. Forward-looking statements are based on the current expectations, estimates, assumptions, and beliefs of management as of the date the relevant statement is made and are necessarily subject to a number of risks, uncertainties, and other factors.

Forward-looking statements are not guarantees of future performance. They involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation:

  • the early-stage nature of the Company’s product development activities, including the transdermal delivery platform currently under development, and the inherent uncertainties associated therewith;
  • the ability to obtain, maintain, and enforce any patents or other intellectual property rights in respect of the Company’s product formulations and delivery technologies;
  • competition from other companies with greater resources, more established distribution networks, and more advanced product pipelines in the peptide wellness and biopharmaceutical sectors;
  • the ability to scale the Company’s distribution network across North America as anticipated and to respond to changes in consumer demand for peptide-based wellness solutions;
  • the potential for adverse regulatory action in Canada, the United States, or other applicable jurisdictions in respect of the Company’s peptide products, including actions by Health Canada, the U.S. Food and Drug Administration, or the Federal Trade Commission relating to product classification, health claims, or advertising practices;
  • changes in laws and regulations applicable to natural health products, consumer wellness products, drug development, and advertising;
  • the availability of financing on acceptable terms, or at all, to fund the Company’s operations, product development, and distribution expansion;
  • the impact of general economic and market conditions, including inflation and interest rate fluctuations, on consumer demand for wellness products;
  • reliance on third-party contract manufacturers, researchers, distributors, and other service providers;
  • risks associated with peptide synthesis and manufacturing scale-up, including challenges in maintaining purity, potency, and identity across production batches;
  • foreign exchange fluctuations, given the Company’s operations and market focus across Canada and the United States; and
  • other risk factors described in the Company’s public filings available on SEDAR+ at www.sedarplus.ca.

The above list of risk factors is not exhaustive. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements.

Readers and investors are cautioned not to place undue reliance on forward-looking statements, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements contained on this website are made as of the date this website was published and are expressly qualified in their entirety by this cautionary note. Except as required by applicable Canadian securities laws or the policies of the Canadian Securities Exchange, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Source References

  1. CNBC, November 21, 2025. Eli Lilly hits $1 trillion market value, first for health care company | BioPharma Dive, April 15, 2026. FDA moves toward easing restrictions on certain peptides
  2. The Joe Rogan Experience #2461, February 27, 2026. Episode with Robert F. Kennedy Jr.
  3. Fox News April 16, 2026. RFK Jr. House Ways and Means testimony coverage
  4. UPI, April 15, 2026. FDA to consider lifting restrictions on peptide injections (Scott Brunner quote)
  5. GlobalData / Fierce Pharma, March 2024. GLP-1s on track to take drug sales throne from PD-1 inhibitors
  6. Fortune, September 5, 2023. Novo Nordisk beats LVMH to become Europe’s most valuable company
  7. CNBC, November 21, 2025. Eli Lilly hits $1 trillion market value
  8. BioPharma Dive, October 30, 2025. Lilly hikes revenue forecasts (Q3 tirzepatide US$10.1B)
  9. eMarketer / Morgan Stanley, November 2025. GLP-1 boom makes Eli Lilly the first $1 trillion pharma company
  10. Grand View Research. Peptide Therapeutics Market 2025–2033
  11. Vasireddi et al., BPC-157: A Systematic Review, HSS Journal, 2025
  12. The New York Times, January 3, 2026. ‘Chinese Peptides’ Are the Latest Biohacking Trend
  13. Bloomberg, September 19, 2025. Do NAD and Peptides Work?
  14. CNN, April 13, 2026. The ‘Wild West’ of peptides is booming
  15. Roche, December 4, 2023. Carmot Therapeutics acquisition (one of several deals totalling $40B+). See: Roche/Carmot; Lilly/Versanis; Novo/Catalent; AZ/CSPC; Novo/Inversago; Novo/Cardior
  16. Alsbrooks & Hoerauf, PLOS ONE, 2022 (63.2% needle phobia among 2,098 adults). Prevalence, causes, impacts, and management of needle phobia
  17. Love & Love, J Primary Care Community Health, 2021 (11.5–66M U.S. adults). Considering Needle Phobia among Adult Patients During Mass COVID-19 Vaccinations
  18. Igarashi et al., REVISE study: Patient preferences oral vs injectable diabetes medications
  19. Pangea Natural Foods Inc. / Amino Innovations, October 21, 2025. Amino Innovations Develops Next-Generation Peptide Patch Platform
  20. The Joe Rogan Experience #1580 — Rogan on BPC-157. Episode commentary documented
  21. Huberman Lab Podcast, April 1, 2024. Benefits & Risks of Peptide Therapeutics
  22. The Doctor’s Farmacy, Ep. 914 with Dr. Edwin Lee. How Peptides Enhance Healing and Longevity
  23. Ben Greenfield, bengreenfieldlife.com. How To Use BPC-157
  24. The Tim Ferriss Show #826, September 10, 2025. Q&A with Tim — Supplements, Recovery, Peptides
  25. Usmani et al., THPdb: Database of FDA-approved peptide and protein therapeutics, PLOS ONE, 2017
  26. Pickart & Margolina, Regenerative and Protective Actions of the GHK-Cu Peptide, Int. J. Mol. Sci., 2018
  27. Sikiric et al., BPC 157 and Stable Gastric Pentadecapeptide, Pharmaceuticals, 2024
  28. Lee et al., MOTS-c: mitochondrial-derived peptide, Cell Metabolism, 2015
  29. Brunel University London Epitalon replication study, 2025. PMC12411320
  30. Pangea Wellness Inc. / TheNewswire, March 13, 2026. Name change to The Precision Peptide Company Inc., effective March 18, 2026
  31. https://www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market#:~:text=The%20global%20peptide%20therapeutics%20market,options%20across%20major%20disease%20areas.